Condition: Kidney Disease · Sponsor: Palatin Technologies, Inc
This is a prospective, open-label trial to assess the efficacy of melanocortin receptor agonist bremelanotide (BMT) when administered with RAAS inhibition therapy after six months in subjects with Type II diabetic nephropathy. After six months of therapy, all subjects will remain in trial for further assessment and undergo a diagnostic renal biopsy to assess the effect of melanocortin therapy on diabetic histopathology at 12 months.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| California Institute of Renal Research | Chula Vista, California, United States | — |
| California Institute of Renal Research DBA - Balboa Research | La Mesa, California, United States | — |
| Georgia Nephrology, LLC DBA -GA Nephrology Research Institute | Decatur, Georgia, United States | — |
| Georgia Nephrology, LLC [DBA] GA Nephrology Research Institute | Lawrenceville, Georgia, United States | — |
| Brookview Hills Research Associates, LLC | Winston-Salem, North Carolina, United States | — |
| Northeast Research Center, LLC | Bethlehem, Pennsylvania, United States | — |
| Nephrotex Research Group | Dallas, Texas, United States | — |
| Prolator Clinical Research Center | Houston, Texas, United States | — |
| Clinical Advancement Center, PLLC | San Antonio, Texas, United States | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05709444